(4R)-4-benzyl-3-[(2R)-2-bromo-3-butylheptanoyl]-1,3-oxazolidin-2-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: (4R)-4-benzyl-3-[(2R)-2-bromo-3-butylheptanoyl]-1,3-oxazolidin-2-one
• 化学式: C₂₁H₃₀BrNO₃
• 分子量: 424.378
• InChiKey: JWRJFYUQAADWBO-RTBURBONSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.7
• 重原子数：
  26
• 可旋转键数：
  10
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (4R)-4-benzyl-3-[(2R)-2-bromo-3-butylheptanoyl]-1,3-oxazolidin-2-one 在 N,N,N',N'-四甲基胍叠氮化物 作用下， 以 乙腈 为溶剂， 生成 (4R)-3-[(2S)-2-azido-3-butylheptanoyl]-4-benzyl-1,3-oxazolidin-2-one
  参考文献：
  名称：

  (S)-N-(5-Chlorothiophene-2-sulfonyl)-β,β-diethylalaninol a Notch-1-sparing γ-secretase inhibitor

  摘要：

  Accumulation of beta-amyloid (A beta), produced by the proteolytic cleavage of amyloid precursor protein (APP) by beta- and gamma-secretase, is widely believed to be associated with Alzheimer's disease (AD). Research around the high-throughput screening hit (S)-4-chlorophenylsulfonyl isoleucinol led to the identification of the Notch-1-sparing (9.5-fold) gamma-secretase inhibitor (S)-N-(5-chlorothiophene-2-sulfonyl)-beta,beta-diethylalaninol 7.b.2 (A beta (40/42) EC50 = 28 nM), which is efficacious in reduction of A beta production in vivo. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.11.116
• 作为产物：
  描述：

  溴丁基-镁 、 (4R)-4-benzyl-3-hept-2-enoyl-1,3-oxazolidin-2-one 在 copper(I) bromide dimethylsulfide complex 、 N-溴代丁二酰亚胺(NBS) 作用下， 以 四氢呋喃 、 二甲基硫 为溶剂， 生成 (4R)-4-benzyl-3-[(2R)-2-bromo-3-butylheptanoyl]-1,3-oxazolidin-2-one
  参考文献：
  名称：

  (S)-N-(5-Chlorothiophene-2-sulfonyl)-β,β-diethylalaninol a Notch-1-sparing γ-secretase inhibitor

  摘要：

  Accumulation of beta-amyloid (A beta), produced by the proteolytic cleavage of amyloid precursor protein (APP) by beta- and gamma-secretase, is widely believed to be associated with Alzheimer's disease (AD). Research around the high-throughput screening hit (S)-4-chlorophenylsulfonyl isoleucinol led to the identification of the Notch-1-sparing (9.5-fold) gamma-secretase inhibitor (S)-N-(5-chlorothiophene-2-sulfonyl)-beta,beta-diethylalaninol 7.b.2 (A beta (40/42) EC50 = 28 nM), which is efficacious in reduction of A beta production in vivo. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.11.116

文献信息

• Heterocyclic sulfonamide inhibitors of beta amyloid production
  申请人：ArQule

  公开号：US20020183361A1

  公开（公告）日：2002-12-05

  Compounds of Formula (I), 1 wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , T, W, X, Y and Z are as defined herein are provided, together with pharmaceutically acceptable salt, hydrates and/or prodrugs thereof. Methods of using these compounds for inhibiting beta amyloid production and for treatment of Alzheimer's Disease and Down's syndrome are described

  提供了符合以下定义的化合物（I）的化合物，其中R1、R2、R3、R4、R5、R6、T、W、X、Y和Z的定义如下，以及其药用盐、水合物和/或前药。描述了使用这些化合物抑制β淀粉样蛋白产生以及治疗阿尔茨海默病和唐氏综合征的方法。
• HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION
  申请人：Kreft Anthony F.

  公开号：US20100022594A1

  公开（公告）日：2010-01-28

  Compounds of Formula (I), wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , T, W, X, Y and Z are as defined herein are provided, together with pharmaceutically acceptable salt, hydrates and/or prodrugs thereof. Methods of using these compounds for inhibiting beta amyloid production and for treatment of Alzheimer's disease and Down's syndrome are described.

  提供式(I)的化合物，其中R1、R2、R3、R4、R5、R6、T、W、X、Y和Z的定义如本文所述，以及其药学上可接受的盐、水合物和/或前药。描述了使用这些化合物抑制β淀粉样蛋白产生和治疗阿尔茨海默病和唐氏综合症的方法。
• Heterocyclic sulfonamide inhibitors of β amyloid production
  申请人：Wyeth

  公开号：US07691884B2

  公开（公告）日：2010-04-06

  Compounds of Formula (I), wherein R1, R2, R3, R4, R5, R6, T, W, X, Y and Z are as defined herein are provided, together with pharmaceutically acceptable salt, hydrates and/or prodrugs thereof. Methods of using these compounds for determining β-amyloid levels in a subject are described.

  本发明提供了化学式（I）的化合物，其中R1，R2，R3，R4，R5，R6，T，W，X，Y和Z的定义如本文所述，并提供其药学上可接受的盐，水合物和/或前药。还描述了使用这些化合物在受试者中确定β-淀粉样蛋白水平的方法。
• Heterocyclic Sulfonamide Inhibitors of Beta Amyloid Production
  申请人：Kreft Anthony F.

  公开号：US20110034513A1

  公开（公告）日：2011-02-10

  Compounds of Formula (I), wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , T, W, X, Y and Z are as defined herein are provided, together with pharmaceutically acceptable salt, hydrates and/or prodrugs thereof. Methods of using these compounds for inhibiting beta amyloid production and for treatment of Alzheimer's disease and Down's syndrome are described.

  提供式(I)的化合物，其中R1、R2、R3、R4、R5、R6、T、W、X、Y和Z的定义如本文所述，以及其药学上可接受的盐、水合物和/或前药。本文描述了使用这些化合物抑制β淀粉样蛋白生成和治疗阿尔茨海默病和唐氏综合症的方法。
• US6610734B2
  申请人：——

  公开号：US6610734B2

  公开（公告）日：2003-08-26